

11131 U.S. PTO IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING NATIONAL PHASE OF
PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495

10/018972

To: 12/26/01
Hon. Commissioner of Patents
Washington, D.C. 20231



00909

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: P 0265292 /HAMY422003
M# /Client Ref.

From: Pillsbury Winthrop LLP, IP Group:

Date: Wednesday, December 26, 2001

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

- | | | |
|------------------------------|------------------------------|-------------------------------------|
| 1. International Application | 2. International Filing Date | 3. Earliest Priority Date Claimed |
| PCT/US00/17394 | 23 June 2000 | 25 June 1999 |
| fr country code | Day MONTH Year | Day MONTH Year |
| | | (use item 2 if no earlier priority) |
4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:

- (a) ☐ 20 months from above item 3 date (b) ☒ 30 months from above item 3 date,
(c) Therefore, the due date (unextendable) is December 25, 2001

5. Title of Invention COMPOUNDS OBTAINED FROM SALVIA SPECIES HAVING ANTIVIRAL ACTIVITY

6. Inventor(s) HAN, Myun K. et al

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

7. ☒ Please immediately start national examination procedures (35 U.S.C. 371 (f))
8. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file if in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:
- a. ☐ Request;
b. ☒ Abstract;
c. 76 pgs. Spec. and Claims;
d. 14 sheet(s) Drawing which are ☐ informal ☒ formal of size ☒ A4 ☐ 11"
9. ☒ A copy of the International Application has been transmitted by the International Bureau.
10. A translation of the International Application into English (35 U.S.C. 371(c)(2))
- a. ☐ is transmitted herewith including: (1) ☐ Request; (2) ☐ Abstract;
(3) _____ pgs. Spec. and Claims;
(4) _____ sheet(s) Drawing which are:
☐ informal ☐ formal of size ☐ A4 ☐ 11"
- b. ☐ is not required, as the application was filed in English.
c. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
d. ☐ Translation verification attached (not required now).

10/018972

531 Rec'd PCT/ 26 DEC 2001

11. ☒ Please see the attached Preliminary Amendment
12. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., **before 18th month from first priority date above in item 3, are transmitted herewith (file only if in English) including:**
13. ☒ PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau
14. ☐ Translation of the amendments to the claims **under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of claim amendments made before 18th month, is attached (required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled).**
15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))
 a. ☐ is submitted herewith ☐ Original ☐ Facsimile/Copy
 b. ☒ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
16. **An International Search Report (ISR):**
 a. Was prepared by ☐ European Patent Office ☐ Japanese Patent Office ☐ Other
 b. ☒ has been transmitted by the international Bureau to PTO
 c. ☒ copy herewith (1 pg(s).) ☒ plus Annex of family members (1 pg(s).)
17. **International Preliminary Examination Report (IPER):**
 a. ☒ has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.
 b. ☒ copy herewith in English.
 c. ☐ IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:
 c.2 ☐ Specification/claim pages # ___ claims # ___
 Dwg Sheets # ___
 d. ☐ Translation of Annex(es) to IPER **(required by 30th month due date, or else annexed amendments will be considered canceled).**
18. **Information Disclosure Statement** including:
 a. ☒ Attached Form PTO-1449 listing documents
 b. ☒ Attached copies of documents listed on Form PTO-1449
 c. ☒ A concise explanation of relevance of ISR references is given in the ISR.
19. ☐ **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.
20. ☐ Copy of Power to IA agent.
21. ☐ **Drawings** (complete only if 8d or 10a(4) not completed): ___ sheet(s) per set: ☐ 1 set informal; ☐ Formal of size ☐ A4 ☐ 11"
22. Small Entity Status ☒ is **Not** claimed ☐ is claimed (**pre-filing confirmation required**)
- 22(a) ___ (No.) Small Entity Statement(s) enclosed (since 9/8/00 Small Entity Statements(s) not essential to make claim)
23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) U.S. of:

	Application No.	Filing Date		Application No.	Filing Date
(1)	09/339,813	June 25, 1999	(2)	_____	_____
(3)	_____	_____	(4)	_____	_____
(5)	_____	_____	(6)	_____	_____

 a. ☒ See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, please proceed promptly to obtain same from the IB.
 b. ☐ Copy of Form PCT/IB/304 attached.

24. Attached:

25 Per Item 17.c2, cancel original pages # __, claims # __, Drawing Sheets # __

26. **Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:**

Based on amended claim(s) per above item(s) ☐ 12, ☐ 14, ☐ 17, ☐ 25 (hilitte)

Total Effective Claims	minus 20 =	x \$18/\$9 =	\$0	969/967
Independent Claims	minus 3 =	x \$84/\$42 =	\$0	964/965
If any proper (ignore improper) Multiple Dependent claim is present,		add \$280/\$140	+0	969/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→ **BASIC FEE REQUIRED, NOW** →→→→

A. If country code letters in item 1 are not "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

See item 16 re:

1. Search Report was <u>not</u> prepared by EPO or JPO -----	add \$1,040/\$520	960/961
2. Search Report was prepared by EPO or JPO -----	add \$890/\$445 +	970/971

SKIP B, C, D AND E UNLESS country code letters in item 1 are "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN", "ZA", "LC" or "PH"

→ <input type="checkbox"/> B. If USPTO did not issue <u>both</u> International Search Report (ISR) and (if box 4(b) above is X'd) the International Examination Report (IPER), -----	add \$1,040/\$520	+0	960/961
(only) → <input type="checkbox"/> C. If USPTO issued ISR but not IPER (or box 4(a) above is X'd), -----	add \$740/\$370	+0	968/969
(these) (4) → <input type="checkbox"/> D. If USPTO issued IPER but IPER Sec. V boxes <u>not</u> all 3 YES, -----	add \$710/\$355	+0	966/967
→ <input checked="" type="checkbox"/> E. If international preliminary examination fee was paid to USPTO and Rules 492(a)(4) and 496(b) <u>satisfied</u> (in IPER Sec. V <u>all</u> 3 boxes <u>must</u> be YES for <u>all</u> claims), --	add \$100/\$50	+100	962/963

27. **SUBTOTAL =** \$ _____

28. If Assignment box 19 above is X'd, add Assignment Recording fee of ---\$40 _____ +0 (581)

29. If box 15a is X'd, determine whether inventorship on Declaration is different than in international stage. If yes, add (per Rule 497(d)) ---\$130 _____ +0 (098)

30. Attached is a check to cover the ----- **TOTAL FEES** \$100 _____

Our Deposit Account No. 03-3975

Our Order No. 082137 0265292

C#

M#



00909

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

Sig: Myra J. Francis

Fax: (703) 905-2500
Tel: (703) 905-2200

Atty/Sec: RLT/mhn

NOTE: File in duplicate with 2 postcard receipts (PAT-103) & attachments 43/601

10018972 041603
10/018972
531 Rec'd PCT 26 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Inventor(s): HAN, Myun K. et al

Filed: Herewith

Title: COMPOUNDS OBTAINED FROM SALVIA SPECIES HAVING ANTIVIRAL
ACTIVITY

December 26, 2001

PRELIMINARY AMENDMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE SPECIFICATION:

At the top of the first page, just under the title, insert

☒ --This application is the National Phase of International Application
PCT/US00/17394 filed June 23, 2000 which designated the U.S.
and that International Application

☒ was ☐ was not published under PCT Article 21(2) in English.--

Respectfully submitted,

PILLSBURY WINTHROP LLP
Intellectual Property Group

By: *Ramin B. Tamei* Reg NO 43,601

Attorney: Robin E. Teskin
Reg. No: 35030
Tel. No.: (703) 905-2200
Fax No.: (703) 905-2500

Atty\Sec. RLT/mhn
1600 Tysons Boulevard
McLean, VA 22102

(703) 905-2000

COMPOUNDS OBTAINED FROM SALVIA
SPECIES HAVING ANTIVIRAL ACTIVITY

FIELD OF THE INVENTION

This invention is related to the use of active agents obtained from extracts of the plant genus *Salvia*. The active ingredients include conjugates of molecules having at least one moiety from β -(3,4-dihydroxyphenyl) lactic acid and/or caffeic acid. The active ingredients are preferably salvianolic acid, its dimers, trimers and tetramers. The active agents, either alone or more preferably in combination, can be administered to a subject to treat a viral infection or virus mediated condition.

BACKGROUND OF THE INVENTION

Salvia miltiorrhiza. The plant, *Salvia miltiorrhiza* (SM), has long been used in traditional Chinese medicine for treatment of cardiovascular and hepatic diseases. Extracts from the plant confer potent hepatoprotective activity both *in vitro* and *in vivo*. Hase *et al.*, *Planta Med.* 63: 22-6 (1997). Magnesium lithospermate B may be one of the main active components of SM that protects the liver (Liu *et al.*, *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 13: 352-3, 326 (1993)). SM also contains antioxidants that apparently aid membrane damage repair when treating viral myocarditis (Meng *et al.*, *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 12: 345-7, 324-5 (1992)). Patients suffering from chronic hepatitis B have responded to treatment with SM and/or *Polyporus Umbellatus* polysaccharide (PUP) (Xiong, *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 13:

-2-

33-5, 516-7 (1993)). Herbal extracts from SM also have demonstrated anti-HIV activity (U.S. Patent No. 5,178,865) and anti-hepatitis activity (International PCT Application 98/24460; Chinese Patent Application Nos. 1,192,922 and 1,192,918). Antiviral agents active against herpes, polio, measles, varicella
5 zoster, cytomegalovirus, DNA viruses and RNA viruses have been described which contain at least one crude drug from the root of *Salvia miltiorrhiza* Bunge (European Patent No. 568,001). *Salvia* extracts have also been prepared as anti-herpes virus agents (U.S. Patent No. 5,411,733).

The SM plant has several components which may be extracted.

- 10 Components of the root have been extracted initially with ethanol, followed by extraction with cold water (SM(1)) or with hot water (SM(2)). Both fractions extracted in water have shown antiviral activity.

- Antiviral agents have been developed which target different points in a virus life cycle. For example, antiviral agents for treating retroviral infections
15 have been developed which target retrovirus specific enzymes such as reverse transcriptase (RT) and integrase. Research continues to identify other antiviral agents to combat diseases such as herpes, hepatitis and influenza.

- Antiviral Agents Against Retroviruses.*** Antiviral agents targeting the integrase protein include peptide inhibitors (U.S. Patent No. 5,578,573), nucleic
20 acid ligand inhibitors (U.S. Patent Nos. 5,756,287 and 5,587,468), as well as compounds such as Equisetin (U.S. Patent Nos. 5,759,842) and ermophilane sesquiterpenoids (U.S. Patent No. 5,858,738). To date, of the numerous

-3-

compounds that have already been identified and approved for marketing by the FDA for HIV, only RT and protease inhibitors have been approved.

- Caffeic Acid as an Antiviral Agent.** Caffeic acid can be isolated from the stems of *Bougainvillea spectabilis* Wild (Nyctaginaceae), which has been used as folk medicine against hepatitis (Chang *et al.*, *Anticancer Res.* 14: 501-6 (1994)). Caffeic acid has been reported to inhibit xanthine oxidase, which is associated with several diseases, *e.g.*, gout, hepatitis and tumors (Chan *et al.*, *Anticancer Res.* 15: 703-7 (1995); and Chang *et al.* (1994)). Caffeic acid oxidation product (KOP) inhibits herpes virus hominis type 1 and type 2 (Thiel *et al.*, *Acta Virol.* 27: 200-8 (1983)). A caffeic acid tetramer and dipotassium and potassium-sodium salts of a caffeic acid tetramer glucoside possess anti-HIV activity according to Kashiwada *et al.*, *J. Nat. Prod.* 58: 392-400 (1995). Commercially produced caffeic acid also has antiviral activity, as demonstrated using a RT assay for HIV (Kreis *et al.*, *Antiviral Res.* 14: 323-37 (1990)).
- Caffeic acid phenethyl esters (CAPE) exert inhibitory activity on the integrase protein of HIV-1 (Fesen *et al.*, *Proc. Natl Acad. Sci. USA* 90: 2399-2403 (1993); Fesen *et al.*, *Biochem. Pharmacol.* 48: 595-608 (1994); Burke *et al.*, *J. Med. Chem.* 38: 4171-8 (1995); Mazumder *et al.*, *J. Med. Chem.* 39: 2472-81 (1996)). However, the method used to prepare caffeic acid polymers influenced their HIV-1 and HIV-2 inhibitory activity (Nakashima *et al.*, *Chem. Pharm. Bull. (Tokyo)* 40: 2102-5 (1992)). Caffeic acid, along with cinnamic acid and rosmarinic acid, have also been proposed for treating influenza virus because of their antioxidant activity (International PCT Application 98/30228).

-4-

- Rosemarinic and Lithospermic Acids as Antiviral Agents.** Rosemarinic acid is a dimer of caffeic acid. A dimer of rosemarinic acid is lithospermate B. Both rosemarinic acid and lithospermic acid have been identified in extracts of SM root (Kohda *et al.*, *Chem. Pharm. Bull. (Tokyo)* 37: 1287-90 (1989)).
- 5 Rosemarinic acid possesses anti-HIV activity (Arda *et al.*, *J. Nat. Prod.* 60: 1170-3 (1997)) and is potentially a Herpes simplex type 1 (HSV-1) inhibitor (Dimitrova *et al.*, *Acta Microbiol. Bulg.* 29: 65-72 (1993)). Rosemarinic acid also has been proposed to treat inflammatory diseases and disorders (U.S. Patent No. 4,329,361).
- 10 **Cinnamic Acid as an Antiviral Agent.** Substituted cinnamic acid esters inhibit the infectious activity of influenza virus A/Hong Kong (H3N2) (Serkedjieva *et al.*, *J. Nat. Prod.* 55: 294-302 (1992)); steryl esters of cinnamic acid derivatives have demonstrated antiviral activity *in vitro* against viruses belonging to *Picornaviridae*, *Orthomyxoviridae*, *Paramyxoviridae* and
- 15 *Herpesviridae* ("Antiviral activity of cholesteryl esters of cinnamic acid derivatives," *Z. Naturforsch* 53: 883-7 (1998); and Conti *et al.*, *Antivir. Chem. Chemother.* 9: 511-5 (1998)). Dehydrogenation polymers of substituted cinnamic acids have also been described as a HIV-1 therapeutic (U.S. Patent Nos. 5,346,695 and 5,632,980).
- 20 **Salvianolic Acid.** Salvianolic acid has not been described in the literature as having antiviral properties. Several forms of salvianolic acid (*e.g.*, salvianolic acid A, acetylsalvianolic acid) have been described as having antioxidant properties (Lin *et al.*, *J. Biochem. Pharmacol.* 51: 1237-1241 (1996)). Salvianolic

-5-

acid has also been indicated for preventing liver injury and fibrosis, associated with its anti-lipid peroxidation actions (Hu *et al.*, *Acta Pharmacol. Sin.* 18: 478-480 (1997)) and for use in treating coronary diseases (Japanese Patent 2,131,423). Additional forms of salvianolic acid described in the literature

5 include those isolated from aqueous extracts of *Salvia cavaleriei* (e.g., salvianolic acids A, B, C H and I) (Zhang *et al.*, *Planta Med.* 60: 70-72 (1994)) or from *S. miltiorrhiza* (e.g., salvianolic acid K, a caffeic acid trimer) (Kasimu *et al.*, *Chem. Pharm. Bull.* 46: 500-504 (1998); and Tezuka *et al.*, *Chem Pharm. Bull.* 46: 107-112 (1998)). Salvianolic acids F 2 and F 3 can be prepared synthetically as

10 described by Dalla *et al.*, *Tetrahedron* 55: 6923-6930 (1999); and Dalla *et al.*, *Tetrahedron Lett.* 39: 8285-8286 (1998). Additional members of the *Salvia* family may be used as sources for obtaining Danshen, including: *S. bowleyana*, *S. deserta*, *S. miltiorrhiza* var. *miltiorrhiza* f. *alba*, *S. paramiltiorrhiza*, *S. paramiltiorrhiza* f. *purpureo-rubra*, *S. przewalskii*, *S. prsewalskii* var.

15 *mandarinorum*, *S. sinica* f. *purpurea*, and *S. trijuga* (Kasiumu *et al.*, 1998). Methods of producing plants with elevated secondary metabolite levels of compounds such as salvianolic acid have also been described. See U.S. Patent No. 5,869,340 (1999).

(3,4-dihydroxyphenyl) lactic acid. A principle component of SM is

20 "Danshensu," chemically known as sodium β -3,4-dihydroxyphenyl lactate (Fen *et al.*, *Acta Acad. Med. Primae Shanghai* 10: 133-6 (1983); Zhao *et al.*, *Chin. Pharm. J.* 29: 291-93 (1994)). It is an intermediate compound used in preparing rosemarinic acid in cell culture (Al-Sereiti *et al.*, *Indian J. Exp. Biol.* 37: 124-130


-6-

(1999); Bogucki *et al.*, *Can. J. Chem.* 75: 1783-94 (1997); and U.S. Patent No. 5,011,775).

Treating virus-mediated diseases with antiviral agents can be quite expensive. For example, HIV-1 treatment using reverse transcriptase and protease inhibitors costs approximately \$12,000-20,000 per patient per year. Given that the majority of HIV infected patients reside in developing nations, additional medications which are more economically attractive must be identified for the treatment of HIV and other viral diseases. The instant invention provides a new method of identifying, making and using novel compounds and compositions thereof for use as antiviral therapeutics.


SUMMARY OF THE INVENTION

One aspect of the invention describes compositions containing molecules having at least one moiety from β -(3,4-dihydroxyphenyl) lactic acid and/or caffeic acid, which are found in extracts from genus *Salvia*, said moieties being of the formula:



-7-

said active agents having a molecular weight of at least 190 daltons. R^1 of the β -



(3,4-dihydroxyphenyl) lactic acid moiety can be either -OH, -O- or a bond, and R^2 can be either -H or a bond. R^3 of the caffeic acid moiety can be either -OH or -O-; R^4 can be either a bond or




- 5 wherein R^3 is -OH or a bond; R^6 can be either -H or a bond; and R^7 can be either -H or a bond.

In another embodiment, a conjugation product is contemplated, which is a homopolymer or heteropolymer of monomeric units of salvianolic acid and/or dehydrogenated forms of salvianolic acid, said conjugation product having a
 10 molecular weight of about 492 or greater, or acetyl, ester, or anhydride derivatives thereof, or pharmaceutically acceptable salts thereof.



-8-

In a preferred embodiment, the conjugation product is a homopolymer or heteropolymer of monomeric units of salvianolic acid (I) and/or dehydrogenated forms (II) or (III) of salvianolic acid, said salvianolic acid having the structure:



and said dehydrogenated forms of salvianolic acid having the structures:


-9-



wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are hydrogen or a bond, and the monomeric units of said homopolymers or heteropolymers are bonded to each other by R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 .


A particularly preferred compound is the dimer of salviannic acid having
 5 the following structures:

-10-




Dimeric Structure of Salvianolic Acid

-11-



Salvianolic Acid

-12-



Dimeric Form

The present invention also relates to a method of making an antiviral agent comprising incubating salivianolic acid at an alkaline pH such that homopolymers or heteropolymers are formed which possess greater antiviral activity than salivianolic acid.

-13-

The agents of the invention possess antiviral activity and may be administered in pharmaceutically acceptable carriers systemically or locally.

BRIEF DESCRIPTION OF THE DRAWINGS

- Fig. 1.* Three-dimensional representation of Compound 5 of Example 4.
- 5 *Fig. 2.* Three-dimensional representation of Compound 6 of Example 4.
- Fig. 3.* Three-dimensional representation of Compound 7 of Example 4.
- Fig. 4.* Three-dimensional representation of Compound 8 of Example 4.
- Fig. 5.* Three-dimensional representation of Compound 9 of Example 4.
- Fig. 6.* Three-dimensional representation of Compound 10 of Example 4.
- 10 *Fig. 7.* Three-dimensional representation of Compound 11 of Example 4.
- Fig. 8.* Three-dimensional representation of Compound 12 of Example 4.
- Fig. 9.* Three-dimensional representation of Compound 13 of Example 4.
- Fig. 10.* Three-dimensional representation of Compound 2 of Example 4 formed by dehydrogenation of carbons 24 and 38 of salvianolic acid.
- 15 *Fig. 11.* Three-dimensional representation of Compound 3 of Example 4 formed by dehydrogenation of carbons 24 and 35 of salvianolic acid.
- Fig. 12.* Three-dimensional representation of Compound 4 of Example 4 formed by dehydrogenation of carbons 27 and 38 of salvianolic acid.
- Fig. 13.* Three-dimensional representation of Compound 24 of Example 4.
- 20 *Fig. 14.* NMR and structure for dimer of salvianolic acid.

DETAILED DESCRIPTION OF THE INVENTION

-14-

This invention uses an alternative approach to develop drugs derived from plant extracts, specifically the extracts from the plant genus *Salvia*. These active agents inhibit viral integration in a variety of different viruses, including retroviruses. In one preferred embodiment, the active agents disclosed inhibit integration of all or a portion of a viral genome into the genome of the host cell. The active agents also may inhibit virus infection, virus progression and/or virus proliferation by interfering at other points in a virus life cycle.

The *Salvia* genus (family *Lamiaceae*) contains about 700 members that are located in the tropical and temperate zones of the world, with some 300 species in Asia, Europe and Africa and 400 species in America (J.C. Willis, A DICTIONARY OF FLOWERING PLANTS AND FERNS (7th edition, Cambridge, University Press, 1966); J. Briquet, *Labiatae*, In DIE NATURLICHEN PFLANZENFAMILIEN Vol. IV, 3a, 183-375 (Engler and Prantl eds., Englemann, Leipzig, 1897). The antiviral compounds and compositions of this invention may be derived from any member of the *Salvia* genus, but preferably from SM and SY.

A. DEFINITIONS

By the terms "viral-inhibiting effective amount," "therapeutically effective amount" or "therapeutically effective dose" is meant that amount of an active agent or active agents that when administered to a subject with a viral infection or virus mediated disease, said infection or disease is ameliorated, or infection

-15-

inhibited to an extent that outweighs any negative side effects caused by the agent or agents. Such agents would be considered "antiviral agents."

By "viral mediated condition" or "virus mediated condition" is meant a disease phenotype associated with a viral infection. For example, AIDS-related
5 complex (ARC) is a condition associated with an HIV-1 infection.



By "antiviral activity" is meant an ability to inhibit or ameliorate a viral infection or a condition associated with a viral infection. Compounds having antiviral activity according to the invention will preferably inhibit infection *in vitro* at a dosage of $\leq 1 \mu\text{M}$, or less preferably less than or equal to about 10 mM
10 *in vitro*.

By "integrase activity" is meant an integrase protein or a protein which can integrate a viral genome or segment of a viral genome into the genome of a host cell. The majority of integrase proteins are associated with members of the *Retroviridae* family of viruses.

By "plant genus *Salvia*" is meant a plant from the genus *Salvia*, the family
15 *Lamiaceae*. Preferred *Salvia* plants for isolation of compounds according to the invention are "*Salvia miltiorrhiza*" or "SM" and "*Salvia yunanesis*" or "SY."

By "conjugated derivatives" or "larger polymers" is meant an active agent which comprises a dimer, trimer, tetramer, *etc.* wherein the monomeric unit is
20 one of the following moieties:

-16-



The conjugated derivatives or large polymers may be homodimers, homotrimers, homotetramers, *etc.*, or heterodimers, heterotrimers, heterotetramers, *etc.*, of the foregoing moieties. One example of a conjugate derivative is lithospermate B which is a dimer of rosmarinic acid which in turn is a dimer of caffeic acid.

-17-

B. VIRUSES

Treatment or inhibition of any viral infection responsive to the antiviral compounds and compositions described herein is within the scope of the present invention. Preferred are viruses of the following virus families: hepatitis viruses, herpes viruses, orthomyxoviruses, papillomaviruses, paramyxoviruses, picornaviruses, polyomaviruses and retroviruses.

Retroviruses. The compounds and compositions described herein preferably will be used to treat retroviral infections. Although retroviruses belong to a clearly defined and relatively homogeneous viral genus, they have been historically subdivided into three taxonomic groupings, primarily on the basis of the pathologic consequences of infection. The oncovirus subgroup includes retroviruses that have the ability to cause neoplastic disease in the infected host, as well as several related, yet apparently benign viruses. Lentiviruses cause slow, chronic diseases that generally, although not always, lack a neoplastic component. Lentiviruses have yet to be clearly associated with any human or animal disease.

Retroviral replication initiates with the intracytoplasmic penetration of the virion core, a process mediated by the specific interaction of the viral envelope glycoprotein with a specific cell surface receptor. Subsequently, a virion-associated RNA-dependent DNA polymerase transcribes the single-stranded RNA genome into a double-stranded linear DNA proviral intermediate (reverse transcription). An integration protein (integrase) specifically recognizes both ends of the viral DNA and removes two nucleotides from the 3' -ends (3' -donor

-18-

processing). The processed viral DNA and integrase then migrate to the nucleus, where a viral integrase covalently links the retroviral genome to host chromosomal DNA (strand transfer), thereby forming the retroviral provirus.

The emergence of human immunodeficiency virus type 1 (HIV-1) as an important human pathogen increased scientific interest in retroviruses. In particular, evidence indicates that the simple life cycle delineated above is not completely descriptive of the replication cycle of all the retroviruses. For example, HIV-1 encodes no fewer than six gene products in addition to the characteristic retroviral Gag, Pol, and Env; these are translated from a novel set of singly spliced and multiply spliced viral mRNA species. At least two of these additional proteins, termed Tat and Rev, act in *trans* to directly regulate HIV-1 gene expression. Therefore, the steps between penetration and proviral integration appeared quite similar for both MLV (murine leukemia virus) and HIV-1, although postintegration events were found to be significantly more complex in the latter. More recently, it has become evident that HIV-1 is merely one of a whole class of animal retroviruses, that are now referred to as "complex" retroviruses. Retroviruses belonging to this complex retroviruses include all lentiviruses, spumaviruses, as well as HTLV-1 and related viruses (Table 1).

TABLE 1: Major taxonomic divisions among retroviruses

20

Category	Subgroup	Prototype	Other examples
Simple retroviruses	C-type retroviruses group A	RSV	ALV, ASV

-19-

	C-type retroviruses group B	MLV	FeLV, MSV, SNV, REV, SSV
	B-type retroviruses	MMTV	
	D-type retroviruses	MPMV	SRV-1
5	Complex retroviruses	Lentiviruses	HIV-1 HIV-2, SIV, visna virus, FIV,
		T-cell leukemia viruses Spuma-	HTLV-1 EIAV HTLV-II, STLV, BLV
		viruses	HSRV SFV, BFV

Abbreviations: RSV, Rous sarcoma virus; ALV, avian leukemia virus; ASV, avian sarcoma virus; FeLV, feline leukemia virus; MSV, murine sarcoma virus; SNV, spleen necrosis virus; REV, reticuloendotheliosis virus; SSV, simian sarcoma virus; MMTV, mouse mammary tumor virus; MPMV, Mason-Pfizer monkey virus; SRV-1, simian retrovirus type 1; STLV, simian T-cell leukemia virus; BFV, bovine foamy virus.

The steps involved in proviral integration appear quite similar for both simple and complex retroviruses. Because of this commonality of mechanism, an inhibitor of retroviral integrase will inhibit a wide range of organisms such as human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), Feline Immunodeficiency Virus (FIV), Feline Leukemia Virus (FeLV), Murine leukemia virus (MuLV), Rous Sarcoma Virus (RSV), Bovine Immunodeficiency Virus (BIV), Human T-Cell Leukemia virus (HTLV). In addition to these retroviruses, the active agents of the invention may be used as inhibitors against integrase-like proteins to inhibit replication other viruses, such as the Hepatitis B virus (HBV).

Other Viruses. The active agents described herein are also contemplated for use in treating viral infections caused by, for example, hepatitis viruses,

-20-

herpes viruses, orthomyxoviruses, papillomaviruses, paramyxoviruses, picornaviruses and polyomaviruses. Preferred viruses to be treated with the active agents described herein include those listed in the table below:

TABLE 2

5

Virus Family	Common Name	Host Animal
Hepadnaviridae	Hepatitis B	Human
	Woodchuck hepatitis virus	Woodchuck
	Duck hepatitis B virus	Avian
Herpesviridae	Herpes simplex virus 1	Human
	Herpes simplex virus 2	Human
	Varicella zoster virus	Human
	Epstein Barr virus	Human
	Cytomegalovirus	Human
	Infectious bovine	Mammal
	Rhinotracheitis virus	
	Bovine mammillitis virus	Mammal
	Equine abortion virus	Mammal
	Pseudorabies virus	Mammal
Orthomyxovirinae	Marek's disease	Avian
	Turkey herpesvirus	Avian
Orthomyxovirinae	Influenza Type A	Many species
	Influenza Type B	Mainly Human
	Influenza Type C	Mainly Human

WO 01/00199

PCT/US00/17394

-21-

Virus Family	Common Name	Host Animal
Papillomavirinae	Bovine Papilloma Virus-1 (BPV-1)	Cattle
	Bovine Papilloma Virus-2 (BPV-2)	Cattle
	Bovine Papilloma Virus-4 (BPV-4)	Cattle
	CRPV	Rabbit
	DPV	Deer
	Human Papilloma Virus-1 (HPV-1)	Human
	HPV-5	Human
	HPV-6	Human
	HPV-8	Human
	HPV-11	Human
	HPV-16	Human
	HPV-18	Human
	HPV-31	Human
	HPV-33	Human
Paramyxovirinae	Human parainfluenza viruses types 1-4	Human
	SV5	Dog
	Mumps Virus	Human
	Newcastle disease virus	Chicken
	Measles virus	Human
	Canine distemper virus	Dog
	Rinderpest virus	Cattle
	Respiratory syncytial virus (RSV)	Human
	Bovine respiratory syncytial virus	Cattle

-22-

Virus Family	Common Name	Host Animal
Picornavirinae	Human polio virus	Human
	Human coxsackievirus	Human
	Human echovirus	Human
	Human enterovirus	Human
	Human hepatitis virus A	Human
	Porcine enteroviruses 1-11	Pig
	Bovine Enteroviruses 1 and 2	Cattle
	Human Rhinovirus 1-100	Human
	Bovine rhinoviruses 1 and 2	Cattle
	Foot-and-mouth disease viruses 1-7	Cattle and Human
Polyomavirinae	Encephalomyocarditis	Horse
	Equine rhinoviruses 1 and 2	
	Polyomavirus	Mouse
	Simian vacuolating virus 40 (SV40)	Monkey
	Lymphotropic papovavirus (LPV)	Monkey
	BKV	Human
	JCV	Human
	Rabbit kidney vacuolating virus (RKV)	Rabbit

See FUNDAMENTAL VIROLOGY (Bernard N. Fields *et al.*, eds., 1991).

C. METHODS OF MAKING THE COMPOUNDS

- 5 The general conditions for preparing the plant extracts from any *Salvia* species, and more preferred from SM and SY, which contain the active agents is as described in Example 1 below. The compounds can be prepared synthetically as follows. Various compounds containing the moieties β -(3,4-dihydroxyphenyl) lactic acid or salvianolic acid and/or caffeic acid were formed
- 10 by incubation of the respective compounds at a concentration of 5 mg/ml in 0.1% NH_4OH for up to 24 hrs. These include the dehydrogenated forms of salvianolic

-23-

acid, conjugated dimers and larger polymers. The preferred period of time is 3-24 hrs. Incubation periods greater than 48 hrs. in 0.1% NH_4OH may result in inactivation of the compound. The period of activation also depends on the starting concentration of the compound. Higher concentrations of compound will require longer periods of incubation for activation. This formation can also occur by adjusting the pH of the compounds in solution to greater than pH= 8 by other alkaline reagents. The reaction is stopped by the addition of an acid, such as 1% acetic acid, such that the pH of the resulting solution is less than or equal to 7. Other factors that can contribute to the formation of new compounds are temperature and oxygenation.

D. PHARMACEUTICAL COMPOSITIONS AND THEIR ADMINISTRATION

For the treatment or mediation of viral infections, a compound according to the invention may be administered orally, topically, parenterally, by inhalation spray or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term "parenteral," as used herein, includes subcutaneous injections, intravenous, intramuscular, intravascular injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, *etc.*, the compounds and compositions described herein are effective in the treatment of virus infections in human subjects.

-24-

For administration to the central nervous system, compositions may be administered into the cerebral spinal fluid. For intrathecal administration, carriers for parenteral administration, particularly carriers such as glucose in water or saline, are appropriate. The compositions may also be prepared in liposomes to enhance transfer across membrane barriers. Compositions may be prepared for transdermal administration via patches. Solvents used for administration of hydrophobic compounds may also be used for this purpose, such as DMSO or oils which cross the dermal barrier.

For parenteral administration, solutions of a therapeutic compound of the present invention may be prepared, for example, using either sesame or peanut oil or aqueous propylene glycol. Aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary, and the liquid diluent first rendered isotonic. Such aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected

-25-

from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active compound or combination of compounds may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the

-26-

active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

The excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, sodium phosphate; 5 granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelation or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated, or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over 10 a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for controlled or timed release.

Aqueous suspensions may contain the active materials in admixture with 15 excipients suitable for the manufacture of aqueous suspensions. Such excipients include suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or 20 condensation products of an alkylene oxide with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty

-27-

acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial ester derived from fatty acids and hexitol anhydrides, for example, polyoxyethylene sorbitan monooleate. The said aqueous suspensions may also contain one or more preservatives, for example, ethyl, or n-
5 propyl p-hydroxybenzoate.

An oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil, such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. These
10 compositions may be preserved by the addition of an antioxidant, such as ascorbic acid.

Dispersible powders and granules are suitable for the preparation of an aqueous suspension by mixing them with water. These compositions may provide the active ingredient in admixture with a dispersing or wetting agent, a
15 suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oils, or a mineral oil, for example, liquid paraffin or mixtures
20 of these. Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth, naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial ester derived from fatty acids and hexitol anhydrides (*e.g.*, sorbitan monooleate), and condensation products of

-28-

the said partial esters with ethylene oxide (*e.g.*, polyoxyethylene sorbitan monooleate).

5 An ointment containing the pharmaceutical compositions of the present invention may be prepared, among other methods known in the art, by combining the active ingredient with a medium consisting of a glycol, a lower alkanol, and water; a gelling agent and optionally an adjuvant such as diisopropyl adipate, diethyl sebacate, ethyl caproate and ethyl laurate. Suitable glycols include propylene glycol, butylene glycol, polyethylene glycol and the like. Generally, a carboxyvinyl polymer preneutralized with an organic amine such as diisopropyl
10 amine and triethylamine, or a cellulose (*e.g.*, hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose) is used as the gelling agent.

The compounds and compositions described herein may also be administered in the form of suppositories for rectal administration of the drug.
15 These compositions can be prepared by mixing the drug with a suitable non-irritating excipient, which is solid at ordinary temperatures such as room temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

20 The amount of an active compound or combination of compounds that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain from about 25 mg to about 1 g of active

-29-

ingredient. Daily dose of the active ingredients will usually range from between about 1 to about 300 mg per kg of body weight for the oral route and from between about 0.1 to 100 mg per kg of body weight for usual injection administration. The quantity may be given at one time or divided into two or
5 more aliquots administered during the course of a day. It will be understood, however, that the specific dose level for any particular patient or subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, the duration of viral
10 infection in the subject being treated, and the severity of the particular viral infection being treated.

The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any effective route, preferably by one of the three routes previously indicated. Such
15 administration may be carried out in single or multiple doses. More particularly, the novel therapeutic agents of this invention can be administered in a wide variety of different dosage forms, *i.e.*, they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories,
20 jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like, as described above.

The examples provided below serve merely to illustrate certain embodiments of the claimed invention and are not meant to limit the invention.

-30-

Example 1Extraction of Antiviral Agents from SM and SY

Plant extracts of SM and SY were prepared as follows:

- Step 1:** Dried SY was boiled in Milli-Q distilled water (dH₂O) (18.0 mOhm/cm) and concentrated to a final density of 1.30 g/ml. The extract was then diluted 1:5 with dH₂O, centrifuged at 8,000 rpm for 90 min at 25°C. in a GS-3 rotor. The pellet was discarded, and the supernatant was saved. To this supernatant a one tenth volume of 1.0 N HCl solution was added to make a final concentration of 0.1 N HCl. This supernatant was incubated overnight at 25°C.
- 10 The solution was centrifuged at 8,000 rpm for 90 min at 25°C. in a GS-3 rotor, and the resulting pellet was then washed with 95% ethanol followed by filtration through a 0.2 μ m filter system. This was repeated until the wash solutions became clear. The pellet was then dried in the filtration unit at room temperature followed by incubation in an oven overnight at 70°C. The powder was
- 15 resuspended in dH₂O at a 1:5 (w/w) ratio of pellet to water. The resulting product was then centrifuged at 25,000 rpm for 30 min at 25°C. in a Ti45 rotor. The supernatant was discarded, and the resulting pellet resuspended in 50% ethanol. Alternatively, the supernatant can also be resuspended in 50% methanol.

- Step 2:** The resuspended solution was filtered to remove the insoluble
- 20 materials.

Step 3: The filtered solution was concentrated to one-fifth (1/5) of the original volume to form a precipitate. The precipitated pellet was washed with

-31-

distilled water. The washed pellet was then freeze-dried overnight. The dried, washed pellet was designated as Fraction 1.

Step 4: The dried powder obtained from step 3 was dissolved in 50% methanol. The solution was centrifuged to remove any insoluble materials. The supernatant solution was applied to a Sephadex LH-20 column equilibrated with distilled water. The column was washed extensively with distilled water and was eluted with the following order of solutions: 15% methanol in water (v/v), 30% methanol with 1% acetic acid in water (v/v), 40% methanol in water (v/v), 50% methanol in water (v/v), 75% methanol in water (v/v), and 100% methanol. The order of solution used depends on the starting solution. The fraction eluted with 50% methanol in water was concentrated and applied to an HPLC reverse column (Ultrasphere ODS, 4.6 x 250 mm, 5 μ M), which was equilibrated with 10% methanol and 0.1% formic acid. The column was eluted using a 25 minute gradient of 10% methanol/0.1% formic acid and 100% methanol/0.1% formic acid at 1 ml/min. Compounds were detected by monitoring the absorbance at 275 nm.

Step 5: Molecular mass of each fraction eluted from the HPLC reverse column was analyzed by mass spectroscopic methods. The mass spec. identified the following compounds:


20	<u>MW</u>	<u>Compounds</u>
1.	180	Caffeic acid (#1)
2.	198	D-(3,4-dihydroxyphenyl) lactic acid (#2)

-32-


- | | | | |
|----|-----|-----|--|
| | 3. | 359 | Rosemarinic acid (#3) |
| | 4. | 387 | Salt forms of rosemarinic acid (Yunnaneic acid
C and Yunnaneic acid D) |
| 5 | 5. | 494 | 2-(3,4-dihydroxyphenylethenyl) caffeic acid (#5) or
salvianolic acid. |
| | 7. | 717 | Lithospermate B (#7) |
| | 8. | 739 | Magnesium lithospermate B (#8) |
| | 9. | 853 | Combination of rosemarinic acid and 2-(3,4-
dihydroxyphenylethenyl) caffeic acid (#9) |
| 10 | 10. | 987 | Dimers of #5 with a MW of 987 (#10), as discussed in
Example 4, below. |

Compounds are of the formulae:


#1



-33-




-34-




-35-

Yunnaneic Acid D




-36-

#5




-37-


#7



#8



-38-



Example 2

Antiviral Assay: Efficacy of Viral Inhibition

***In vitro* HIV-1 Integrase Assay:** *In vitro* assays to monitor the activity of HIV-1 integrase have been developed, as described below. These assays utilize purified recombinant HIV-1 integrase and oligonucleotide substrates which represent the LTR ends of the viral DNA. The functional significance of data obtained from the *in vitro* assays relies on the assays reflecting the actual functional events which occur *in vivo*. Both fluorometric (Lee *et al.*, *Analytical Biochemistry* 227: 295-301 (1995)) and radioactive assays have been developed

-39-

- which improve upon the previously published *in vitro* assay (Lee *et al.*, *Biochemistry* 34: 10205-10214 (1995); Lee *et al.*, *Biochemistry* 34: 10215-10223 (1995)). In addition, we have modified the enzyme preparation, which has improved the quality of the HIV-1 integrase sample (Lee and Han, *Biochemistry* 35: 3837-3844 (1996); Lee *et al.*, *Biochemistry* 36: 173-180 (1997)). These modifications to the *in vitro* assay and sample preparation have been included to better reflect the events occurring *in vivo*. Therefore, the results from the *in vitro* assay are very useful predictors of viral infectivity when searching for potential integrase inhibitors.
- 10 The activity of Fraction 1 in inhibiting HIV-1 integrase was determined as follows. Fraction 1 was first dissolved in the appropriate volume of 0.1% NH_4OH (w/v) to make the final concentration 15 mg/ml. These samples were then centrifuged at 10,000 rpm for 30 min. If a pellet was formed, then the supernatant was removed; the pellet was dried down and then redissolved in
- 15 0.1% NH_4OH . The resulting solution is the stock solution of the extract fractions. From this stock, the following dilutions were made: 1:10, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, 1:2000, 1:3000, 1:4000, 1:5000, and 1:10,000. 1 μl of each of these dilutions was added to each reaction mixture which corresponds to a final concentration of 75, 15, 7.5, 3.75,
- 20 2.5, 1.875, 1.5, 1.25, 1.07, 0.9375, 0.833, 0.75, 0.375, 0.25, 0.1875, 0.15 and 0.075 $\mu\text{g/ml}$, respectively. Testing was then carried out as previously described (Lee *et al.*, *Biochemistry* 34: 10205-10214 (1995); Lee *et al.*, *Biochemistry* 34: 10215-10223 (1995); Lee and Han (1996)).

-40-

To determine the IC_{50} and IC_{90} of each fraction, the gel was exposed to a PHOSPHORIMAGER™ screen and the percent cleavage determined by the Molecular Dynamics PHOSPHORIMAGER™. The percent inhibition was determined by subtracting percent cleavage of each fraction from the percent cleavage of the positive control and dividing this value by the percent cleavage of the positive control. The results demonstrated that Fraction 1 had an IC_{50} of 0.2-1.2 $\mu\text{g/ml}$ and an IC_{90} of 2.5-3.5 $\mu\text{g/ml}$ in the culture media. Accordingly, in the live mammal, blood concentrations of up to about 100X that level may be tolerated and beneficial.

Example 3

Testing SM Extracts *In Vitro*

The Feline Immunodeficiency Virus (FIV) model is an accepted animal model for studying drugs for use against HIV infection. FIV is a T cell-trophic lentivirus isolated from felines. FIV resembles HIV biologically and biochemically, which includes high homology between FIV and HIV integrase. FIV infected cats develop Feline Acquired Immunodeficiency Syndrome (FAIDS), which is similar to full-blown AIDS in humans.

***In vitro* FIV model in cell culture:** The Crandell-Reese Feline kidney (CrFK) cell line is susceptible to FIV infection and supports viral replication. CrFK cells are an efficient means for producing virus and assaying for FIV infection. Although FIV is not cytopathic for FIV infected CrFK cells, diagnostic

-41-

assays are available for screening for FIV infection in tissue culture. Studies have demonstrated the efficacy of SY.

Determination of ED₅₀: Fraction 1 was tested for protection of CrFK cells from FIV infection. In triplicate, CrFK cells were plated at a density of 1×10^5 cells/T25 flask. Following a 24 hr incubation for cell attachment and growth, solutions of compounds were applied to the cell cultures for 24 hr. The solutions were made by dissolving the active agents of the invention in phosphate buffer, at pH 8 at a concentration of 100 mg/ml, which was then centrifuged at 25,000 rpm for 30 min at 25°C. in a Ti45 rotor. The supernatant solution was removed, and three 1 ml aliquots were dried down by centrifugation under an open vacuum for determining the concentration of the solution. The active agent is further diluted down to 2 mg/ml, filtered through a 0.2 μ m acetate cellulose filter, and the concentration determined by determining the mass of the dried solute compared to the tared control.


The results demonstrated that Fraction 1 had an ED₅₀ range between 0.1 and 1.0 μ g/ml and an ED₉₀ range between 0.2 and 2.5 μ g/ml in preventing FIV infection of CrFK cells. Given these results, compositions of the invention may be administered in pharmaceutically acceptable carriers and should be administered in sufficient dosage to obtain a blood concentration of 10 nM to 1000 nM. However, in some instances it is necessary to administer doses to obtain concentration of up to 10,000 nM in the blood. The more active agents may be effective at blood concentration of as low 1 nM.

-42-

Example 4Conjugation of salvianolic acid.

Under alkaline conditions, salvianolic acid (Compound 1) may generate three additional dehydrogenated forms (Compounds 2-4). The conjugation of salvianolic acid and its derivatives (dehydrogenated forms of salvianolic acid) to dimeric forms results in the formation of several compounds whose structures are shown. These conjugations are the result of homodimers and/or heterodimers of salvianolic acid with its dehydrogenated forms. These compounds show anti-HIV-1 integrase activity at concentrations less than 1 $\mu\text{g/ml}$.

10 The base structure of salvianolic acid, Compound 1, is shown (see below):




-43-


- A, B, C, and D represent the hydrogens at carbons 24, 27, 35, and 38, respectively, of Compound 1. These hydrogens are the potential sites of conjugation. Therefore, the conjugation of salvianolic acid to itself (Compound 1), a homodimer, will result in the formation of the following combinations
- 5 (Compounds 5-13): Compound 5 is A conjugated to A (Fig. 1); Compound 6 is A conjugated to B (Fig. 2); Compound 7 is A conjugated to C (Fig. 3); Compound 8 is A conjugated to D (Fig. 4); Compound 9 is B conjugated to B (Fig. 5); Compound 10 is B conjugated to C (Fig. 6); Compound 11 is C conjugated to C (Fig. 7); Compound 12 is C conjugated to D (Fig. 8); Compound 13 is D
- 10 conjugated to D (Fig. 9); Compound 24 is B of Compound 1 conjugated to D of Compound 1 (Fig. 13). Figure 14 contains the structure and NMR spectra of a preferred salvianolic acid dimer according to the invention.

- The three dehydrogenated forms of salvianolic acid (Compounds 2-4) that can be formed by dehydrogenation at carbons 24 and 38, carbons 24 and 35, and
- 15 carbons 27 and 38. These forms have the following base structures:
- Compound 2, 24-38 (Fig. 10):

-44-




Compound 3, 24-35 (Fig. 11):



E represents the site of conjugation.

Compound 4, 27-38 (Fig. 12):

-45-



F represents the site of conjugation.

The dehydrogenated forms of salvianolic acid (Compounds 2-4) can form homodimers. This means that compound 3 can conjugate with itself at site E to form Compound 14, and Compound 4 conjugates with itself at site F to form Compound 15.

These dehydrogenated forms can also form heterodimers with salvianolic acid. The potential heterodimers that are formed are A of Compound 1 conjugated with E of Compound 3 to form Compound 16; B of Compound 1 conjugated with E of Compound 3 to form Compound 17; C of Compound 1 conjugated with E of Compound 3 to form Compound 18; D of Compound 1 conjugated with E of Compound 3 to form Compound 19; F of Compound 4 conjugated with A of Compound 1 to form Compound 20; F of Compound 4 conjugated with B of Compound 1 to form Compound 21; F of Compound 4 conjugated with C of Compound 1 to form Compound 22; and F of Compound 4 conjugated with D of Compound 1 to form Compound 23.

-46-

In addition to these dimers, it is possible to form trimers and larger polymers of these species. The variations in structure of these compounds will be known to those skilled in the art.

- It is also envisioned that these compounds can be modified to contain acetyl groups, esters, anhydrides or pharmaceutically acceptable salts of the compound.

Example 5

Time dependent activation of anti-integrase activity as a result of conjugation.

- Compound 1 of Example 4 was purified and confirmed by both Mass Spectrometry and NMR. Compound 1 was then incubated with 0.1 % NH_4OH for various time periods (5 min., 30 min., 1 hr., 2 hrs., 3 hrs., 4 hrs., 5 hrs. and 24 hrs.) at a concentration of 5 mg/ml. The reactions were stopped by the addition of 1% acetic acid and assayed for anti-HIV-1 integrase activity. The results demonstrate that there is a time-dependent activation of the fractions as a result of incubation in 0.1% NH_4OH . This activation is the result of various conjugations of Compound 1. The results are displayed in Table 3:

TABLE 3

Time pH 6.0	IC_{50} ($\mu\text{g/ml}$)
pH = 6.0	3.5
5 min.	1.8

-47-

Time pH 6.0	IC ₅₀ (µg/ml)
30 min.	1.7
1 hr.	1.5
2 hrs.	1.5
3 hrs.	1.05
4 hrs.	1.0
5 hrs.	0.9
24 hrs.	0.5

Purified compounds having a MW of 492 (*e.g.*, compounds 2-4, as described above) were incubated with 0.1% NH₄OH for various time periods (5 min., 30 min., 1 hr., 1.5 hr., 2.0 hrs., and 3.0 hrs.) at a concentration of 5.0 mg/ml. The reactions were stopped by the addition of 1% acetic acid and assayed for anti-HIV-1 integrase activity. The results demonstrate that there is a time-dependent activation of Compounds 2-4 as a result of incubation in 0.1% NH₄OH. This activation, however, is not as great as conjugations with Compound 1. The results are shown in Table 4:

-48-

TABLE 4

Sample	IC 50
5 min.	> 7.5
30 min.	5.5
1 hr.	5.2
1.5 hrs.	4.2
2.0 hrs.	4.1
3.0 hrs	2.1

Example 6Anti-HIV-1 Integrase Activity of Activated Compound 1.

0.8 g of Compound 1 of Example 4 was incubated in 80 ml of 0.1% NH_4OH to a final concentration of 10 mg/ml for 8 hrs. This activated fraction was then applied to an SEPHADEX® LH20 column and eluted with increasing concentrations of methanol in water. The eluted fractions were lyophilized and assayed for anti-HIV-1 integrase activity. The results are shown in Table 5:

TABLE 5

Fraction	IC ₅₀ (μg/ml)
Original	1.1
10% Methanol	1.1
20% Methanol	0.69
30% Methanol	0.81
40% Methanol	0.92

-49-

Fraction	IC ₅₀ (µg/ml)
50% Methanol	0.4
60% Methanol	0.92
70% Methanol	3.2
80% Methanol	>7.5

5 The 50% sample, which had the best activity, was then analyzed by mass spectrometry. The mass spectra showed two major peaks of 492 and 986. These peaks correspond to a monomer of salvianolic acid and a dimer of salvianolic acid, indicating that these species represent the active anti-viral principles. Therefore, these results suggest that the active anti-viral agent responsible for the inhibition of integrase is either salvianolic acid and/or its dimeric form.

10

The efficacy of these fractions against HIV-1 infection was evaluated using CEM^{TART} cells. These cells are engineered from CEM as described in Example 8. The HIV p24 antigen capture assay was used as described in Example 8. The results are discussed in Table 6 below:

TABLE 6

Sample	IC 50 (µg/ml)
10%	41
20%	2.2
30%	12
40%	7
50%	3.8
60%	40

20

-50-

Sample	IC 50 (µg/ml)
70%	40
80%	Not Determined

Example 7Anti-HIV-1 integrase activity.

- 5 Fraction 1 of Example 1 was dissolved in 40% of methanol (in water) and centrifuged for 30 min. at 8,000 rpm in a GSA rotor. The supernatant fraction was loaded onto a SEPHADEX® LH20 column equilibrated in 40% methanol (in water). The column was washed with 40% methanol solution (in water) and eluted with 50, 60, 70, 80 and 90% of methanol solution (in water). The samples
- 10 were then lyophilized and dissolved in the appropriate volume of methanol to make the final stock concentration 5 mg/ml. These fractions were then assayed for anti-HIV-1 integrase activity. The concentrations assayed were 5, 2.5, 2, 1.5, 1.25, 1, 0.8, 0.6, 0.4, and 0.2 µg/ml. The percent of inhibition was determined by subtracting the percent of cleavage of each fraction from the percent of cleavage
- 15 of the positive control and dividing this value by the percent of cleavage of the positive control.

-51-

TABLE 7

Results of *In vitro* HIV-1 Integrase Activity Assay

# Fractions	IC ₅₀ (μg/ml)
40	0.84
50	0.70
60	0.68
70	0.60
80	0.57
90	0.50

- 10 SEPHADEX® LH20 column fractions of 60-80% were combined and dissolved in 40% of methanol in water. The resuspended sample was centrifuged for 30 min at 8,000 rpm in a GSA rotor. The supernatant solution was applied to MCI GEL CHP20P (75-150μ) column equilibrated with 40% methanol in water. The column was washed with 40% methanol in water and eluted with 50, 60, and
- 15 70% of methanol in water. The sample was then lyophilized and assayed as previously described under various conditions.

-52-

TABLE 8

Results of *In vitro* HIV-1 Integrase Activity Assay

# samples	IC ₅₀ in MeOH (µg/ml)	IC ₅₀ in pH 6.0 (µg/ml)	IC ₅₀ in 0.1% NH ₄ OH (µg/ml)
MCI 40	0.32	0.70	0.44
MCI 50	0.34	0.80	0.58
MCI 60	0.42	1.00	0.62

The MCI GEL CHP20P (75-150µ) samples were then analyzed by Mass Spectrometry Analysis (negative mode). The results show that MCI 40 has a major peak of 986 with a minor peak of 494. The MCI 50 has major peaks of 492 and 986. MCI 60 has major peaks of 984 and 986. It was determined that the 494 peak represents salvianolic acid as determined by Mass Spectrometry and NMR. The 492 peak represents the dehydrogenated form of salvianolic acid. The 986 peak represents a dimeric form of salvianolic acid. The 984 peak represents the mixed dimer of 492 and 494. These results indicate that the active principles of Fraction 1 are a Compound having a molecular weight of 984 and/or 986. These experimental data suggest that the dimeric compounds of molecular weight 984 and 986 are generated from Compound 1.

Example 8Assaying the Anti-HIV-1 Activity of an Active Agent

The efficacy of the MCI GEL CHP20P (75-150µ) fractions against HIV-1 infection was evaluated with CEM^{TART} cells. These cells are engineered from

-53-

CEM cells and consitutively express HIV-1 *tat* and *rev* genes. CEM^{TART} cells provide a safe system for assessing HIV infection as they have been engineered to be productive for a replication incompetent form of the HIV-1, HIV^{Δ*tat/rev*}. The efficacy of the compounds to inhibit HIV-1 infection was evaluated using the

5 HIV p24 antigen capture assay. This assay uses p24 core protein monoclonal antibody coated 96 well plates in which cell culture media or serum was incubated for 2 hrs. The supernatants were removed from cells at least 1 week following infection with HIV^{Δ*tat/rev*}. The wells were washed prior to the addition of a biotinylated polyclonal antibody to HIV-1 p24. Following addition of

10 substrate for signal amplification, p24 expression is directly quantified relative to the known standard.

MCI 40, 50 and 60 were dissolved in methanol, and the ability of these compounds to inhibit HIV-1 infection was assessed at the following concentrations: 100, 20, 10, 5, and 1 μg/ml. To 24 well tissue culture dishes, 2

15 ml of 3.33×10^4 CEM^{TART} cells were added together with the test concentrations of compound. To this 5000 TCID₅₀/10⁶ cells of HIV-1 inoculum was added. The culture medium was changed twice weekly such that 0.8 ml of cell suspension was resuspended in 2 ml of replacement medium. Cell-free supernatants were then assayed for the presence of p24. Anti-HIV-1 efficacy was then evaluated by

20 comparing HIV-1 p24 antigen production in the presence and absence of added drug after 7 and 10 days. The results are shown in Tables 9 and 10:

-54-

TABLE 9: Day 7

Sample	Concentration ($\mu\text{g/ml}$)	% Inhibition
MCI 40	100	100
	20	100
	10	100
	1	0
MCI 50	100	100
	20	100
	10	100
	1	0
MCI 60	100	100
	20	100
	10	100
	1	0

5

TABLE 10: Day 10

Sample	Concentration ($\mu\text{g/ml}$)	% Inhibition
MCI 40	100	100
	20	100
	10	100
	1	0
MCI 50	100	100
	20	100
	10	100
	1	0

-55-



Sample	Concentration ($\mu\text{g/ml}$)	% Inhibition
MCI 60	100	100
	20	100
	10	100
	1	0

All references discussed above are hereby incorporated by reference.

-56-

WHAT WE CLAIM IS:

1. A method of treating or preventing a viral infection by administering a composition containing a viral-inhibiting effective amount of at least one active agent having at least one moiety of the formulae:




5 wherein R^1 is -OH, -O- or a bond; R^2 is -H or a bond; R^3 is -OH or -O-; R^4 is a bond or




wherein R^5 is -OH or a bond; R^6 is -H or a bond; and R^7 is -H or a bond, said active agent having a molecular weight of more than 190 daltons.

-57-

2. The method according to claim 1, wherein said active agent has at least one moiety of the formula:




and at least one moiety of the formula:



3. The method according to claim 1, wherein the active agent is a dimer, trimer, tetramer or larger polymer of said moieties.

-58-

4. The method according to claim 1, wherein the active agents are chosen from among D-(2,3-dihydroxyphenyl) lactic acid, rosmarinic acid, 2-(3,4-dihydroxyphenylethenyl) caffeic acid, lithospermate B, magnesium lithospermate B, dimers of 2-(3,4-dihydroxyphenylethenyl) caffeic acid, or



5. The method of claim 1, wherein said compound is a dimer of salvanolic acid.

-59-

6. The method of claim 5, wherein said compound has the structure depicted in Figure 14.

7. The method according to claim 1, wherein the viral infection is caused by a hepatitis virus, orthomyxovirus, papillomavirus, paramyxovirus,
5 picornavirus, polyomavirus or retrovirus.


8. The method according to claim 7, wherein the retrovirus is HIV or FIV.

9. The method according to claim 7, wherein the viral infection is caused by a virus that produces integrase or a protein which has integrase
10 activity.


10. The method according to claim 1, wherein the composition is administered intranasally, orally, transdermally, parenterally, intrathecally or intravenously.

-60-

11. A method of treating a subject or preventing a viral infection by administering to a subject in need thereof a composition comprising a viral-inhibiting effective amount of two or more active agents and at least two of said



active agents comprise at least one of the following formulae:



-61-

wherein R¹ is -OH, -O- or a bond; R² is -H or a bond; R³ is -OH or -O-; R⁴ is a bond or




wherein R⁵ is -OH or a bond; R⁶ is -H or a bond; and R⁷ is -H or a bond, said active agents having a molecular weight of more than 190 daltons.

5 12. The method according to claim 11, wherein the active agent is a dimer, trimer, tetramer or larger polymer of said moieties.

13. The method according to claim 11, wherein the active agents are chosen from among D-(2,3-dihydroxyphenyl) lactic acid, rosemarinic acid, 2-(3,4-dihydroxyphenylethenyl) caffeic acid, lithospermate B, magnesium
10 lithospermate B, dimers of 2-(3,4-dihydroxyphenylethenyl) caffeic acid, or

-62-



14. The method according to claim 11, wherein the viral infection is caused by a hepatitis virus, orthomyxovirus, papillomavirus, paramyxovirus, picornavirus, polyomavirus or retrovirus.



15. The method according to claim 14, wherein the retrovirus is HIV or

-63-

16. The method according to claim 14, wherein the viral infection is caused by a virus that produces integrase or a protein which has integrase activity.

17. The method according to claim 11, wherein the composition is administered intranasally, orally, transdermally, parenterally, intrathecally or intravenously.

18. An anti-viral composition comprising two or more active agents, wherein the active agents contain at least one of the following moieties:



wherein R¹ is -OH, -O- or a bond; R² is -H or a bond; R³ is -OH or -O-; R⁴ is a

10 bond or



-64-



wherein R⁵ is -OH or a bond; R⁶ is -H or a bond; and R⁷ is -H or a bond, said active agents having a molecular weight of more than 190 daltons; wherein said composition is capable of inhibiting a viral infection when administered to a subject in need thereof.

- 5 19. A compound having the structure depicted in Figure 14.
20. A method of identifying antiviral agents from the plant genus *Salvia* comprising the steps of:
- (a) extracting an active agent from the plant comprising one of either of the following moieties or a conjugate of said moiety

-65-



wherein R^1 is -OH, -O- or a bond; R^2 is -H or a bond; R^3 is -OH or -O-; R^4 is a bond or



wherein R^5 is -OH or a bond; R^6 is -H or a bond; and R^7 is -H or a bond; and

- (b) combining said first active agent with a second active agent
- 5 comprising a moiety or conjugate thereof not represented by first said active agent; and

(c) assaying the combination of said first active agent and said second active agent for antiviral activity.

-66-

21. A conjugation product which is a homopolymer or heteropolymer of monomeric units of salvianolic acid and/or dehydrogenated forms of salvianolic acid, said conjugation product having a molecular weight of about 492 or greater, or acetyl, ester, or anhydride derivatives thereof, or
- 5 pharmaceutically acceptable salts thereof.

22. The conjugation product according to claim 21, which has a molecular weight ranging from about 492 to about 986.


23. The conjugation product according to claim 22, which has a molecular weight of about 492.

- 10 24. The conjugation product according to claim 22, which has a molecular weight of about 984.

25. The conjugation product according to claim 22, which has a molecular weight of about 986.



-67-

26. The conjugation product according to claim 22, which is a homopolymer or heteropolymer of monomeric units of salvianolic acid and/or dehydrogenated forms II or III of salvianolic acid, said salvianolic acid having the structure:



5 and said dehydrogenated forms of salvianolic acid having the structures:

-68-



wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are hydrogen or a bond, and the monomeric units of said homopolymers or heteropolymers are bonded to each other by R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 .

-69-

27. The conjugation product of claim 26 which is a homodimer.

28. The conjugation product of claim 27, wherein the monomeric units are bonded together by a bond which is R^1-R^1 , R^2-R^2 , R^3-R^3 , R^4-R^4 , R^5-R^5 , or R^6-R^6 .

5 29. The conjugation product of claim 27, wherein the monomeric units are bonded together by a bond which is R^1-R^2 , R^1-R^3 , R^1-R^4 , R^2-R^3 , R^2-R^4 , or R^3-R^4 .

30. The conjugation product of claim 26 which is a heterodimer.

31. The conjugation product of claim 30, wherein the monomeric units
10 are bonded together by a bond which is R^1-R^5 , R^2-R^5 , R^3-R^5 , or R^4-R^5 .

32. The conjugation product of claim 30, wherein the monomeric units are bonded together by a bond which is R^1-R^6 , R^2-R^6 , R^3-R^6 , R^4-R^6 , or R^5-R^6 .

-70-

33. The conjugation product of claim 20 which is a homotrimer.

34. The conjugation product of claim 20 which is a heterotrimer.

35. The conjugation product of claim 20 which is a homopolymer of 4 or more monomeric units.

5 36. The conjugation product of claim 20 which is a heteropolymer of 4 or more monomeric units.

37. A method of treating or preventing a viral infection by administering a composition containing a viral-inhibiting effective amount of a conjugation product according to claim 20.

10 38. The method according to claim 37, wherein the conjugation product is a homodimer, heterodimer, homotrimer or heterotrimer.

-71-

39. The method according to claim 37, wherein the viral infection is caused by a hepatitis virus, orthomyxovirus, papillomavirus, paramyxovirus, picornavirus, polyomavirus or retrovirus.

40. The method according to claim 39, wherein the retrovirus is HIV or
5 FIV.

41. The method according to claim 39, wherein the viral infection is caused by a virus that produces integrase or a protein which has integrase activity.

42. The method according to claim 37, wherein the conjugation product
10 is administered intranasally, orally, transdermally, parenterally, intrathecally or intravenously.

43. A method of making an antiviral agent comprising incubating salvianolic acid at an alkaline pH such that homopolymers or heteropolymers are formed which possess greater antiviral activity than salvianolic acid.

-72-

44. The method according to claim 43, wherein the homopolymers or heteropolymers have a molecular weight of about 492 or greater.

45. The method according to claim 43, wherein the homopolymers or heteropolymers have a molecular weight ranging from about 492 to about 986.

5 46. The method according to claim 45, wherein the homopolymers or heteropolymers have a molecular weight of about 492.


47. The method according to claim 45, wherein the homopolymers or heteropolymers have a molecular weight of about 984.

10 48. The method according to claim 45, wherein the homopolymers or heteropolymers have a molecular weight of about 986.

49. The method according to claim 45, wherein the homopolymers or heteropolymers comprise monomeric units of salvianolic acid and/or



-73-

dehydrogenated forms II or III of salvianolic acid, said salvianolic acid having the structure:



and said dehydrogenated forms of salvianolic acid having the structures:

-74-



wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are hydrogen or a bond, and the monomeric units of said homopolymers or heteropolymers are bonded to each other by R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 .

-75-

50. The method according to claim 49, wherein a homodimer is formed.

51. The method according to claim 50, wherein the monomeric units are bonded together by a bond which is R^1-R^1 , R^2-R^2 , R^3-R^3 , R^4-R^4 , R^5-R^5 , or R^6-R^6 .

52. The method according to claim 50, wherein the monomeric units are
5 bonded together by a bond which is R^1-R^2 , R^1-R^3 , R^1-R^4 , R^2-R^3 , R^2-R^4 , or R^3-R^4 .

53. The method according to claim 49, wherein a heterodimer is formed.

54. The method according to claim 53, wherein the monomeric units are bonded together by a bond which is R^1-R^5 , R^2-R^5 , R^3-R^5 , or R^4-R^5 .

55. The method according to claim 43, wherein the monomeric units are
10 bonded together by a bond which is R^1-R^6 , R^2-R^6 , R^3-R^6 , R^4-R^6 , or R^5-R^6 .

56. The method according to claim 53, wherein a homotrimer is formed.

-76-

57. The method according to claim 43, wherein a heterotrimer is formed.

58. The method according to claim 43, wherein a homopolymer of 4 or more monomeric units is formed.

59. The method according to claim 43, wherein a heteropolymer of 4 or
5 more monomeric units is formed.

10/018 992
10018972.001603
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)



PCT

(10) International Publication Number
WO 01/00199 A1

- (51) International Patent Classification: A61K 31/05. (74) Agent: TESKIN, Robin; Pillsbury Winthrop LLP, 1100 31/74, 31/235, 31/765, 35/78 New York Avenue, N.W., Washington, DC 20005 (US).
- (21) International Application Number: PCT/US00/17394 (81) Designated States (national): CA, JP, US.
- (22) International Filing Date: 23 June 2000 (23.06.2000) (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/339,813 25 June 1999 (25.06.1999) US Published: with international search report
- (71) Applicant (for all designated States except US): GEORGETOWN UNIVERSITY [US/US]; 3900 Reservoir Road, N.W., Washington, DC 20007 (US). (48) Date of publication of this corrected version: 13 June 2002
- (72) Inventors; and (15) Information about Correction: see PCT Gazette No. 24/2002 of 13 June 2002, Section II
- (75) Inventors/Applicants (for US only): HAN, Myun, K. [US/US]; 2742 Sweet Clover Court, Silver Spring, MD 20904 (US). LEE, Paul [US/US]; 3827 Blenheim Road, Phoenix, MD 21131 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: COMPOUNDS OBTAINED FROM *Salvia* SPECIES HAVING ANTIVIRAL ACTIVITY



(A)

(57) Abstract: Compositions are provided containing molecules having at least one moiety from β -(3,4-dihydroxyphenyl) lactic acid and/or caffeic acid, which are found in extracts from the plant genus *Salvia*, said moieties being of formula (A): the active agents having a molecular weight of at least 190 daltons. A class of preferred agents are those which are conjugated to form dimers, trimers, tetramers and larger polymers containing said moieties, with the most preferred being salvianolic acid dimers, trimers, tetramers and larger polymers. The compounds and compositions may be administered in pharmaceutically acceptable carriers and excipients systemically or locally to treat viral infections.

WO 01/00199 A1



2/14




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

MUSJ 04 108

8/14




FIG. 8

9/14




FIG. 9

10/14




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B



018972 1041603

FOR UTILITY/DESIGN
CIP/PCT NATIONAL/PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONSRULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICEPW
FORM

I, the below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED **Compounds Obtained**
from Salvia Species having Antiviral Activity

the specification of which (CHECK applicable BOX(ES))

X ☐ A ☐ is attached hereto.
BOX(ES) ☒ B ☐ was filed on December 26, 2001 as U.S. Application No. 10/018,972
☒ C ☐ was filed as PCT International Application No. PCT/ US00/17394 on June 23, 2000
and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 119(a)(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S)

Number	Country	Date first Filed, open or Published	Date Patented or Granted	Priority NOT Claimed
--------	---------	--	-----------------------------	----------------------

If more prior foreign applications, X box at bottom and continue on attached page.

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL NONPROVISIONAL AND/OR PCT APPLICATION(S)

Application No. (series code/serial no.)	Day/MONTH/Year Filed	Status	Priority NOT Claimed
09/339,813	June 25, 1999	pending, abandoned, patented	
PCT/US00/17394	June 23, 2000	Patented	
		Pending	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop LLP, Intellectual Property Group, telephone number (703) 905-2000 (to whom all communications are to be directed), and persons of that firm who are associated with USPTO Customer No. 909 (see below label) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete from that Customer No. names of persons no longer with their firm, to add new persons of their firm to that Customer No., and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above firm and/or an attorney of that firm in writing to the contrary.

USE ONLY FOR
PILLSBURY WINTHROP

00909

00909

(1) INVENTOR'S SIGNATURE:

Date:

Name	Myun	K	HAN	
	First	Middle Initial	Family Name	
Residence	Silver Spring	MD/US	MD	US
	City	State/Foreign Country	Country of Citizenship	
Mailing Address	4000 Reservoir Rd., NW, Washington, DC			
(include Zip Code)	20007			

(2) INVENTOR'S SIGNATURE:

Date:

Name	Paul		LEE	
	First	Middle Initial	Family Name	
Residence	Phoenix	MD/US	MD	US
	City	State/Foreign Country	Country of Citizenship	
Mailing Address	4000 Reservoir Rd., NW, Washington, DC - 3827 Blenheim Rd., Phoenix MD			
(include Zip Code)	20007 - 21131 SR			

- ☐ FOR ADDITIONAL INVENTORS see attached page.
☐ See additional foreign priorities on attached page (incorporated herein by reference).

Atty. Dkt. No. P0265292
(M#) OCT 17 2002

OFFICE OF PETITIONS

PAT-115CN 2002

declaration

FOR UTILITY/DESIGN
CIP/PCT NATIONAL/PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONS

RULE 63 (37 C.F.R. 1.53)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PW
FORM

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION entitled COMPOUNDS OF QUINAZOLINE

from Sigma Species Naming Antiviral Activity

the specification of which (check applicable BOX(ES))

A. ☐ is attached hereto.

BOX(ES) ☒ B was filed on December 26, 2001

as U.S. Application No. 10018 872

☒ C was filed as PCT International Application No. PCT/ US99/17394 on June 23, 2000

and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendments referred to therein. I acknowledge the duty to disclose as information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim to have made the invention under 35 U.S.C. 111(a)(1) or 35(a)(1) of any foreign application (PCT) application, except as the subject matter is defined and claimed in the application in addition to that disclosed in such prior application. I acknowledge the duty to disclose as information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application, or (2) if no priority claimed, between the filing date of this application.

PRIOR FOREIGN APPLICATIONS:

Number	Country	Date First Filed open or Published	Date Patenting or Granted	Priority NOT Claimed

EXCISE AND TRADE APPLICATIONS: I state as follows and continue as required here.

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 111(a) or 35 U.S.C. 365(c) of the indicated United States applications listed below and any PCT international applications listed above or below, as, if there is a continuation-in-part (CIP) application, except as the subject matter is defined and claimed in the application in addition to that disclosed in such prior application. I acknowledge the duty to disclose as information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application.

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATIONS:

Application No. US99/17394

Application No. US99/17394

June 23, 1999

June 23, 2000

Status	Priority NOT Claimed
pending, abandoned, patented	
Patented	
Pending	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and I believe the statements were made with the knowledge that such statements and the law so involve are punishable by law or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent arising thereon.

And I hereby appoint Pharmix Holding L.P., Intellectual Property Group, telephone number (703) 925-2000 (to whom all communications are to be addressed), and persons of that firm and not associated with USPTO Customer No. 900 (800 666 3600) individually and collectively my attorney to prosecute the application and to conduct all business as the Patent and Trademark Office requires them and with the resulting patent, and I hereby authorize them to execute from this Customer no letters of purpose no longer with their firm, to add new persons at their firm to this Customer no., and to act and rely on communications from and communicate directly with the patenting/prosecuting attorney application information and otherwise as shall be from time to time by whomsoever I hereby declare that I have consented after full disclosure to be represented understand I instruct the above firm and/or an attorney of that firm to bring to the country.

USE ONLY FOR
PALLADIUM WITHDRAWAL

00909

(1) INVENTOR'S SIGNATURE:

Name	Myon	K	HAN	Date:	10/17/02
Residence	Silver Spring	MD/US	Family Name	US	
Mailing Address	4000 Reservoir Rd. NW, Washington, DC	Some Foreign Country	Country of Citizenship		
(include Zip Code)	20907				

(2) INVENTOR'S SIGNATURE:


Name	Paul	LEE	Date:	
Residence	Proctor	MD/US	Family Name	US
Mailing Address	4000 Reservoir Rd. NW, Washington DC	Some Foreign Country	Country of Citizenship	
(include Zip Code)	20907			

- ☐ FOR ADDITIONAL INVENTORS see attached page
☐ See additional foreign priorities on attached page (incorporated herein by reference)

Atty. Dkt. No. P0265292

(MW)

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) 2 of Transmittal ~~was~~ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

☐ *Scanned copy is best available.*